Search peptides, terms, sources/
Immune and longevity

KPV

Also known as: Lys-Pro-Val · alpha-MSH · melanocortin tripeptide KPV

Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Preliminary evidence (level 1 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

4 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. KPV is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Animal studies4 animal studies

What is KPV?

KPV is a three-amino-acid peptide (lysine-proline-valine) that matches the last three amino acids of alpha-MSH, studied in cell and animal models of inflammation, mainly colitis in mice and rats. It is not licensed in the UK, and a registry search on 14 November 2026 found no human trial of KPV.

Class
Melanocortin-derived tripeptide (alpha-MSH fragment)
Origin
Fragment / derived
UK status
Not licensed in the UK
Best study type
Animal studies
Evidence last reviewed

How does KPV work?

In cell experiments, KPV was taken up by human gut and immune cell lines through a short-peptide transporter called PepT1, and at very low concentrations it reduced inflammatory signalling. In mice it reduced signs of colitis in two models. All of this is cell or animal work, and none of it shows the same effect in people.

The mechanism in more detail

In cell experiments, KPV was taken up by human intestinal and immune cell lines through PepT1, a transporter for short peptides that becomes more active in inflamed bowel. At very low concentrations it reduced NF-κB and MAP kinase signalling and the release of inflammatory messengers in those cells.

In mice, KPV reduced signs of colitis in two different models. In one study it still helped mice that lack a working melanocortin-1 receptor, so its action may not depend only on the receptor that alpha-MSH uses. A separate mouse study of brain injury reported a smaller area of damage and less nerve-cell death after one injection, although not every inflammation marker fell.

All of this is cell or animal work. A mechanism seen in cell lines and rodents is not the same as an effect shown in people, and no human trial of KPV was found (see Research Findings).

Mechanisms and targets

Anti-inflammatory / cytokine modulationNF-kB and MAP kinase signalling inhibition (in vitro)PepT1-mediated cellular uptakePepT1 (SLC15A1) peptide transporter

Classification and structure

Names
KPV; Lys-Pro-Val; alpha-MSH(11-13); melanocortin tripeptide KPV
Class
Melanocortin-derived tripeptide (alpha-MSH fragment)
Origin
Fragment / derived
Structure
Tripeptide, Lys-Pro-Val (KPV): the C-terminal three amino acids, positions 11 to 13, of alpha-MSH.
Routes used in the research
Oral (in drinking water) and rectal in the cited animal colitis studies; injection in the cited mouse brain-injury study; applied to cultured cells in the laboratory work. Not studied in people. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

KPV has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
40001

PepT1 uptake, cells and mice Preliminary

In human intestinal and T-cell lines, KPV was taken into cells through the PepT1 transporter and, at nanomolar concentrations, reduced NF-kB and MAP kinase signalling and the release of inflammatory messengers. Given by mouth in drinking water, it reduced the occurrence of colitis in two chemically induced mouse models, shown by lower inflammatory cytokine expression. The authors proposed KPV as a candidate for inflammatory bowel disease.

Study type
Animal
Population
Human cell lines (intestinal epithelial and T cells) and mice with chemically induced colitis
Source
1 Dalmasso et al., 2008

Limitation: Cell lines and mice only.

Limitations in full

Cell lines and mice only. The abstract gives no effect sizes or group sizes. Mouse colitis models do not reproduce human inflammatory bowel disease.

Two mouse colitis models Preliminary

In mice with chemically induced colitis, KPV led to earlier recovery and greater regain of body weight, less inflammatory cell infiltration and lower colonic myeloperoxidase activity (a marker of inflammatory cells). It also reduced inflammation in a T-cell transfer colitis model. In mice with a non-functional melanocortin-1 receptor, KPV kept all treated animals alive, which the authors took to mean its effect is at least partly independent of that receptor.

Study type
Animal
Population
Mice, three experimental set-ups (two colitis models and a receptor-deficient strain)
Source
2 Kannengiesser et al., 2008

Limitation: Mouse work only.

Limitations in full

Mouse work only. The abstract states the results as significant but gives no numbers or group sizes.

Rat colitis, gel formulation Preliminary

A 2021 formulation study placed KPV in a gel to keep it stable. Given rectally to rats with chemically induced colitis, the gel reduced weight loss and disease scores, prevented shortening of the colon, lowered colonic myeloperoxidase and cytokines (TNF-alpha, IL-6), and restored the gut lining. The authors proposed it as a strategy for ulcerative colitis.

Study type
Animal
Population
Rats with chemically induced colitis
Source
3 Sun et al., 2021

Limitation: The study mainly tested a delivery gel, not KPV in people.

Limitations in full

The study mainly tested a delivery gel, not KPV in people. Rat model only. The abstract gives no group sizes or statistics.

Mouse brain-injury study Preliminary

In male mice with experimental traumatic brain injury, a single injection of alpha-MSH(11-13), the KPV sequence, 30 minutes after injury was followed by a smaller secondary lesion and less nerve-cell death. Microglial activation fell, but TNF-alpha, IL-1 beta and the total count of microglial cells did not.

Study type
Animal
Population
Male C57BL mice with controlled cortical impact injury
Source
4 Schaible et al., 2013

Limitation: One mouse study.

Limitations in full

One mouse study. The result was mixed: some inflammation markers fell and others did not. No human data.

No human trial found Not graded

A search of the ClinicalTrials.gov registry on 14 November 2026 found no registered study with KPV or Lys-Pro-Val as an intervention, and a Europe PMC search for clinical-trial publications also found none. Every effect reported on this page comes from cell or animal experiments.

Study type
Clinical trial registry entry
Population
Not applicable (registry search)
Source
5 ClinicalTrials.gov, 2026

Limitation: A search on one date.

Limitations in full

A search on one date. It shows that no registered trial was found, not that none exists: unregistered work and other names would be missed.

What safety findings have been reported?

1 safety finding is recorded for KPV. A short list does not mean a substance is safe; it reflects what has been studied and reported.

No human safety data

No human trial of KPV was found, so there are no human safety, tolerability or pharmacokinetic data. The animal and cell studies cited on this page were designed to look for anti-inflammatory activity, and their abstracts do not report toxicity testing. Animal results cannot be used to judge safety in people.

Source
5 ClinicalTrials.gov, 2026

What is KPV's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Not a licensed medicine. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for KPV (Lys-Pro-Val).
Prescription status
Not applicable, no licensed UK product was found to classify.
Medicine class
Not classified as a licensed medicine in the UK.
MHRA position
No KPV-specific MHRA notice was identified in this review. The review did not include a systematic search of MHRA enforcement releases. Supplying an unlicensed product for human use as a medicine falls under the Human Medicines Regulations 2012.
Authorised use
None.
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. KPV is recorded as not licensed in the UK (checked 14 November 2026).

References

6 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. GastroenterologyIn-vitro, Animal-preclinical · DOI 10.1053/j.gastro.2007.10.026 · PMID 18061177 · Original ↗
  2. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel DiseasesAnimal-preclinical · DOI 10.1002/ibd.20334 · PMID 18092346 · Original ↗
  3. Sun J, Xue P, Liu J, Huang L, Lin G, Ran K, Yang J, Lu C, Zhao Y-Z, Xu H-L (2021). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomaterials Science & EngineeringAnimal-preclinical · DOI 10.1021/acsbiomaterials.1c00792 · PMID 34547895 · Original ↗
  4. Schaible EV, Steinsträßer A, Jahn-Eimermacher A, Luh C, Sebastiani A, Kornes F, Pieter D, Schäfer MK, Engelhard K, Thal SC (2013). Single administration of tripeptide α-MSH(11-13) attenuates brain damage by reduced inflammation and apoptosis after experimental traumatic brain injury in mice. PLoS OneAnimal-preclinical · DOI 10.1371/journal.pone.0071056 · PMID 23940690 · Original ↗
  5. U.S. National Library of Medicine (ClinicalTrials.gov registry) (2026). ClinicalTrials.gov registry search for KPV (Lys-Pro-Val) as an intervention, checked 14 November 2026. ClinicalTrials.govClinical trial registry entry · Original ↗
  6. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about KPV

What is KPV?

KPV is a three-amino-acid peptide (lysine-proline-valine) that matches the last three amino acids of alpha-MSH, studied in cell and animal models of inflammation, mainly colitis in mice and rats. It is not licensed in the UK, and a registry search on 14 November 2026 found no human trial of KPV. Read what it is.

Is KPV licensed in the UK?

PeptGuru records KPV's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on KPV show?

PeptGuru records 5 research findings for KPV: 4 from animal studies and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for KPV?

1 safety finding is recorded, including: no human safety data. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for KPV?

All 6 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · KPV added: 5 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • Thymosin Alpha-1Thymalfasin

    Immune-regulating peptide studied in sepsis, pancreatitis and hepatitis B. Not licensed in the UK; meta-analyses show mixed results.

    Immune and longevityHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Oxytocin

    Natural hormone licensed in the UK for obstetric use; studied separately for social cognition, with mostly negative trial results.

    Hormonal signallingHuman trialsEvidence reviewed
    LimitedLicensed for a different use
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • SemaxACTH heptapeptide analog

    Synthetic ACTH-derived peptide studied for brain function and stroke recovery. Not licensed in the UK; evidence is mainly rodent studies.

    Brain and moodHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare KPV with Thymosin Alpha-1

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.